BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Bethencourt A, Martí V, López-Mínguez JR, Angel J, Mantilla R, Morís C, Cequier A. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol. 2006;47:2152-2160. [PMID: 16750678 DOI: 10.1016/j.jacc.2005.10.078] [Cited by in Crossref: 125] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Sousa-uva M, Neumann F, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, Wijns W, Glineur D, Aboyans V, Achenbach S, Agewall S, Andreotti F, Barbato E, Baumbach A, Brophy J, Bueno H, Calvert PA, Capodanno D, Davierwala PM, Delgado V, Dudek D, Freemantle N, Funck-brentano C, Gaemperli O, Gielen S, Gilard M, Gorenek B, Haasenritter J, Haude M, Ibanez B, Iung B, Jeppsson A, Katritsis D, Knuuti J, Kolh P, Leite-moreira A, Lund LH, Maisano F, Mehilli J, Metzler B, Montalescot G, Pagano D, Petronio AS, Piepoli MF, Popescu BA, Sádaba R, Shlyakhto E, Silber S, Simpson IA, Sparv D, Tavilla G, Thiele H, Tousek P, Van Belle E, Vranckx P, Witkowski A, Zamorano JL, Roffi M, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, Mcdonagh TA, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Sousa-uva M, Simpson IA, Zamorano JL, Pagano D, Freemantle N, Sousa-uva M, Chettibi M, Sisakian H, Metzler B, İbrahimov F, Stelmashok VI, Postadzhiyan A, Skoric B, Eftychiou C, Kala P, Terkelsen CJ, Magdy A, Eha J, Niemelä M, Kedev S, Motreff P, Aladashvili A, Mehilli J, Kanakakis I, Becker D, Gudnason T, Peace A, Romeo F, Bajraktari G, Kerimkulova A, Rudzītis A, Ghazzal Z, Kibarskis A, Pereira B, Xuereb RG, Hofma SH, Steigen TK, Witkowski A, de Oliveira EI, Mot S, Duplyakov D, Zavatta M, Beleslin B, Kovar F, Bunc M, Ojeda S, Witt N, Jeger R, Addad F, Akdemir R, Parkhomenko A, Henderson R; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-Thoracic Surgery 2019;55:4-90. [DOI: 10.1093/ejcts/ezy289] [Cited by in Crossref: 208] [Cited by in F6Publishing: 154] [Article Influence: 52.0] [Reference Citation Analysis]
2 Teirstein PS. Drug-Eluting Stent Restenosis: An Uncommon Yet Pervasive Problem. Circulation 2010;122:5-7. [DOI: 10.1161/circulationaha.110.962423] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
3 Sardella G, Colantonio R, De Luca L, Conti G, Di Roma A, Mancone M, Canali E, Benedetti G, Fedele F. Comparison between balloon angioplasty and additional coronary stent implantation for the treatment of drug-eluting stent restenosis: 18-month clinical outcomes. Journal of Cardiovascular Medicine 2009;10:469-73. [DOI: 10.2459/jcm.0b013e3283297c23] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
4 Alfonso F, Pérez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, García-Touchard A, Martí V, Lozano I, Angel J, Hernández JM, López-Mínguez JR, Melgares R, Moreno R, Seidelberger B, Fernández C, Hernandez R; RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv 2012;5:728-37. [PMID: 22814777 DOI: 10.1016/j.jcin.2012.03.017] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 7.2] [Reference Citation Analysis]
5 Hirose S, Ashikaga T, Hatano Y, Yoshikawa S, Sasaoka T, Maejima Y, Isobe M. Treatment of in-stent restenosis with excimer laser coronary angioplasty: benefits over scoring balloon angioplasty alone. Lasers Med Sci 2016;31:1691-6. [DOI: 10.1007/s10103-016-2039-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
6 Hachinohe D, Jeong MH, Kim MC, Cho KH, Ahmed K, Hwang SH, Lee MG, Sim DS, Park KH, Kim JH, Hong YJ, Ahn Y, Kang JC. Drug-eluting stent as an option for intractable in-stent coronary restenosis. Korean Circ J 2011;41:677-80. [PMID: 22194765 DOI: 10.4070/kcj.2011.41.11.677] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Liu S, Yang Y, Jiang S, Xu H, Tang N, Lobo A, Zhang R, Liu S, Yu T, Xin H. MiR-378a-5p Regulates Proliferation and Migration in Vascular Smooth Muscle Cell by Targeting CDK1. Front Genet 2019;10:22. [PMID: 30838018 DOI: 10.3389/fgene.2019.00022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
8 Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García Del Blanco B, Seidelberger B, Iñiguez A, Gómez-Recio M, Masotti M, Velázquez MT, Sanchís J, García-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, López-Mínguez JR, Moreu J, Martí V, Moreno R, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C; RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol 2014;63:1378-86. [PMID: 24412457 DOI: 10.1016/j.jacc.2013.12.006] [Cited by in Crossref: 169] [Cited by in F6Publishing: 125] [Article Influence: 21.1] [Reference Citation Analysis]
9 Pleva L, Kukla P, Kusnierova P, Zapletalova J, Hlinomaz O. Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study. Circ Cardiovasc Interv 2016;9:e003316. [PMID: 27069104 DOI: 10.1161/CIRCINTERVENTIONS.115.003316] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
10 Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008;97:773-81. [PMID: 18536865 DOI: 10.1007/s00392-008-0682-5] [Cited by in Crossref: 190] [Cited by in F6Publishing: 126] [Article Influence: 13.6] [Reference Citation Analysis]
11 Garg P, Cohen DJ, Gaziano T, Mauri L. Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents. Journal of the American College of Cardiology 2008;51:1844-53. [DOI: 10.1016/j.jacc.2008.01.042] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
12 Kyaw H, Johal G, Gedela M, Barman N, Kini A, Sharma SK. Is Coronary Brachytherapy Staging a Comeback for the Treatment of In-Stent Restenosis? Curr Cardiol Rep 2021;23:156. [PMID: 34599432 DOI: 10.1007/s11886-021-01582-4] [Reference Citation Analysis]
13 Ota H, Mahmoudi M, Torguson R, Satler LF, Suddath WO, Pichard AD, Waksman R. Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis. Cardiovascular Revascularization Medicine 2015;16:151-5. [DOI: 10.1016/j.carrev.2015.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Douglas JS. Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions 2012;5:738-40. [DOI: 10.1016/j.jcin.2012.03.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
15 Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The Problem With Composite End Points in Cardiovascular Studies. Journal of the American College of Cardiology 2008;51:701-7. [DOI: 10.1016/j.jacc.2007.10.034] [Cited by in Crossref: 190] [Cited by in F6Publishing: 156] [Article Influence: 13.6] [Reference Citation Analysis]
16 Patti G, Di Sciascio G. Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: a proposed algorithm based on individual risk stratification. Catheter Cardiovasc Interv 2010;75:128-34. [PMID: 19670304 DOI: 10.1002/ccd.22200] [Reference Citation Analysis]
17 Basavarajaiah S, Latib A, Shannon J, Naganuma T, Sticchi A, Bertoldi L, Costopoulos C, Figini F, Carlino M, Chieffo A, Montorfano M, Colombo A. Drug-eluting balloon in the treatment of in-stent restenosis and diffuse coronary artery disease: real-world experience from our registry. J Interv Cardiol 2014;27:348-55. [PMID: 24815951 DOI: 10.1111/joic.12129] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
18 Looser PM, Kim LK, Feldman DN. In-Stent Restenosis: Pathophysiology and Treatment. Curr Treat Options Cardio Med 2016;18. [DOI: 10.1007/s11936-015-0433-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Alfonso F, García J, Pérez-Vizcayno MJ, Hernando L, Hernandez R, Escaned J, Jiménez-Quevedo P, Bañuelos C, Macaya C. New stent implantation for recurrences after stenting for in-stent restenosis: implications of a third metal layer in human coronary arteries. J Am Coll Cardiol 2009;54:1036-8. [PMID: 19729123 DOI: 10.1016/j.jacc.2009.04.082] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
20 Alraies MC, Darmoch F, Tummala R, Waksman R. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol 2017; 9(8): 640-651 [PMID: 28932353 DOI: 10.4330/wjc.v9.i8.640] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
21 Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-2619. [PMID: 25173339 DOI: 10.1093/eurheartj/ehu278] [Cited by in Crossref: 3051] [Cited by in F6Publishing: 2245] [Article Influence: 381.4] [Reference Citation Analysis]
22 Mintz GS. Features and parameters of drug-eluting stent deployment discoverable by intravascular ultrasound. Am J Cardiol 2007;100:26M-35M. [PMID: 17950829 DOI: 10.1016/j.amjcard.2007.08.019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
23 Rivero F, Cuesta J, Bastante T, García-Guimaraes M, Alfonso F. Treatment options for stent restenosis: insights from intracoronary imaging, clinical trials, and registries. Coron Artery Dis 2017;28:507-17. [PMID: 28562383 DOI: 10.1097/MCA.0000000000000511] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schömig A, Kastrati A; ISAR-DESIRE 2 Investigators. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010;55:2710-6. [PMID: 20226618 DOI: 10.1016/j.jacc.2010.02.009] [Cited by in Crossref: 155] [Cited by in F6Publishing: 110] [Article Influence: 12.9] [Reference Citation Analysis]
25 Moussa ID, Mohananey D, Saucedo J, Stone GW, Yeh RW, Kennedy KF, Waksman R, Teirstein P, Moses JW, Simonton C. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. Journal of the American College of Cardiology 2020;76:1521-31. [DOI: 10.1016/j.jacc.2020.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
26 Kokkinidis DG, Waldo SW, Armstrong EJ. Treatment of coronary artery in-stent restenosis. Expert Review of Cardiovascular Therapy 2017;15:191-202. [DOI: 10.1080/14779072.2017.1284588] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
27 Wang X, Lu W, Wang X, Pan L, Fu W, Liu Q, Han Z, Sun G, Qin X, Li R, Zheng X, Shan Y, Qiu C. Drug-coated balloon angioplasty: predicting outcomes based on different patterns of drug-eluting stent restenosis. Int J Cardiovasc Imaging 2020;36:171-8. [PMID: 31919705 DOI: 10.1007/s10554-019-01681-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
28 Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, Schulz S, Fusaro M, Ott I, Ibrahim T. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381:461-467. [PMID: 23206837 DOI: 10.1016/s0140-6736(12)61964-3] [Cited by in Crossref: 270] [Cited by in F6Publishing: 46] [Article Influence: 27.0] [Reference Citation Analysis]
29 Freixa X, Almasood AS, Khan SQ, Mackie K, Osten M, Ing D, Overgaard CB, Horlick EM, Seidelin PH, Džavík V. Choice of stent and outcomes after treatment of drug-eluting stent restenosis in highly complex lesions. Cathet Cardiovasc Intervent 2013;81:E16-22. [DOI: 10.1002/ccd.24291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Kim KH, Kim DI, Kim IH, Kim JY, Han YC, Seol SH, Kim U, Yang TH, Kim DK, Kim DS, Lee SH, Park JS, Kim YJ, Shin DG, Cho YK, Nam CW, Hur SH, Kim KB. Therapeutic strategy for in-stent restenosis based on the restenosis pattern after drug-eluting stent implantation. Korean Circ J 2009;39:408-13. [PMID: 19949585 DOI: 10.4070/kcj.2009.39.10.408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
31 Alfonso F, Dutary J, Paulo M, Pérez-vizcayno MJ. Paclitaxel-Eluting Balloons for Sirolimus-Eluting Stent Restenosis. JACC: Cardiovascular Interventions 2011;4:716. [DOI: 10.1016/j.jcin.2011.03.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Song H, Park D, Kim Y, Ahn J, Kim W, Lee J, Kang S, Lee S, Lee CW, Park S, Han S, Seong I, Lee N, Lee B, Lee K, Lee S, Nah D, Park S. Randomized Trial of Optimal Treatment Strategies for In-Stent Restenosis After Drug-Eluting Stent Implantation. Journal of the American College of Cardiology 2012;59:1093-100. [DOI: 10.1016/j.jacc.2011.11.047] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
33 Alfonso F, Pérez-Vizcayno MJ, Cuesta J, García Del Blanco B, García-Touchard A, López-Mínguez JR, Masotti M, Zueco J, Cequier A, Velázquez M, Moreno R, Mainar V, Domínguez A, Moris C, Molina E, Rivero F, Jiménez-Quevedo P, Gonzalo N, Fernández-Pérez C; RIBS IV Study Investigators (Under the Auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology). 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents. JACC Cardiovasc Interv 2018;11:981-91. [PMID: 29798776 DOI: 10.1016/j.jcin.2018.02.037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 9.7] [Reference Citation Analysis]
34 Gao Z, Xu B, Yang YJ, Yuan JQ, Chen J, Chen JL, Qiao SB, Wu YJ, Yan HB, Gao RL. Long-term outcomes of drug-eluting stent therapy for in-stent restenosis versus de novo lesions. J Interv Cardiol 2013;26:550-5. [PMID: 24118174 DOI: 10.1111/joic.12069] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
35 Dibra A, Kastrati A, Alfonso F, Seyfarth M, Pérez-Vizcayno MJ, Mehilli J, Schömig A. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol 2007;49:616-23. [PMID: 17276188 DOI: 10.1016/j.jacc.2006.10.049] [Cited by in Crossref: 118] [Cited by in F6Publishing: 81] [Article Influence: 7.4] [Reference Citation Analysis]
36 Yates DJ, Savage ML, Walters DL, Raffel OC. Retrospective Study of First-Generation Drug-Eluting Stents, Second-Generation Drug-Eluting Stents and Non-Drug Eluting Stent Methods in the Treatment of Native Vessel In-Stent Restenosis in Real-World Clinical Practice. Heart, Lung and Circulation 2016;25:342-51. [DOI: 10.1016/j.hlc.2015.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Yeh RW, Bachinsky W, Stoler R, Bateman C, Tremmel JA, Abbott JD, Dohad S, Batchelor W, Underwood P, Allocco DJ, Kirtane AJ. Rationale and design of a randomized study comparing the agent drug coated balloon to plain old balloon angioplasty in patients with In-stent restenosis. Am Heart J 2021;241:101-7. [PMID: 34314727 DOI: 10.1016/j.ahj.2021.07.008] [Reference Citation Analysis]
38 Beohar N, Meyers SN, Erdogan A, Harinstein ME, Pieper K, Gagnon S, Davidson CJ. Off-label use of drug-eluting versus bare metal stents: a lesion-specific systematic review of long-term outcomes. J Interv Cardiol 2010;23:528-45. [PMID: 20735712 DOI: 10.1111/j.1540-8183.2010.00588.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
39 Kufner S, Kastrati A. Drug-eluting stents for drug-eluting stent restenosis: stick with the old or switch to a new one? Coron Artery Dis 2014;25:633-5. [PMID: 25365642 DOI: 10.1097/MCA.0000000000000171] [Reference Citation Analysis]
40 Alfonso F, Pérez-vizcayno MJ, Cárdenas A, García del Blanco B, García-touchard A, López-minguéz JR, Benedicto A, Masotti M, Zueco J, Iñiguez A, Velázquez M, Moreno R, Mainar V, Domínguez A, Pomar F, Melgares R, Rivero F, Jiménez-quevedo P, Gonzalo N, Fernández C, Macaya C. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents. Journal of the American College of Cardiology 2015;66:23-33. [DOI: 10.1016/j.jacc.2015.04.063] [Cited by in Crossref: 182] [Cited by in F6Publishing: 138] [Article Influence: 26.0] [Reference Citation Analysis]
41 Redfors B, Généreux P, Witzenbichler B, Maehara A, Weisz G, McAndrew T, Mehran R, Kirtane AJ, Stone GW. Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. Am Heart J 2018;197:142-9. [PMID: 29447774 DOI: 10.1016/j.ahj.2017.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
42 Kastrati A, Joner M, Kufner S. What Treatment Should We Dare in Patients With In-Stent Restenosis? JACC: Cardiovascular Interventions 2018;11:284-6. [DOI: 10.1016/j.jcin.2017.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Ajani AE, Yan BP, Clark DJ, Eccleston D, Walton A, Lew R, Meehan A, Brennan A, Reid C, Duffy SJ; Melbourne Interventional Group (MIG) Investigators. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents. Heart Lung Circ 2007;16:269-73. [PMID: 17419097 DOI: 10.1016/j.hlc.2007.02.089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
44 Pal N, Din J, O'Kane P. Contemporary Management of Stent Failure: Part One. Interv Cardiol 2019;14:10-6. [PMID: 30858886 DOI: 10.15420/icr.2018.39.1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
45 Grines CL. Off-Label Use of Drug-Eluting Stents. Journal of the American College of Cardiology 2008;51:615-7. [DOI: 10.1016/j.jacc.2007.10.028] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
46 Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol 2014;11:13-23. [DOI: 10.1038/nrcardio.2013.165] [Cited by in Crossref: 119] [Cited by in F6Publishing: 92] [Article Influence: 13.2] [Reference Citation Analysis]
47 Martin DM, Boyle FJ. Drug-eluting stents for coronary artery disease: a review. Med Eng Phys 2011;33:148-63. [PMID: 21075668 DOI: 10.1016/j.medengphy.2010.10.009] [Cited by in Crossref: 81] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
48 Richardt G, Leschke M, Abdel-wahab M, Toelg R, El-mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann F, Widimsky P. Clinical Outcomes of the Resolute Zotarolimus-Eluting Stent in Patients With In-Stent Restenosis. JACC: Cardiovascular Interventions 2013;6:905-13. [DOI: 10.1016/j.jcin.2013.04.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
49 Kutcher MA, Brennan JM, Rao SV, Dai D, Anstrom KJ, Mustafa N, Sedrakyan A, Booth ME, Douglas PS, Messenger JC. Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: A report from the National Cardiovascular Data Registry: PCI-ISR Treatment Strategies. Cathet Cardiovasc Intervent 2014;83:171-81. [DOI: 10.1002/ccd.25108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
50 Ge H, Zhang Q, Zhou W, He Q, Han ZH, He B. Efficacy and safety of drug-eluting stent implantation for the treatment of in-stent restenosis occurring within bare-metal stent and drug-eluting stent. J Zhejiang Univ Sci B. 2010;11:553-560. [PMID: 20669344 DOI: 10.1631/jzus.b1001002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
51 Habara S, Iwabuchi M, Inoue N, Nakamura S, Asano R, Nanto S, Hayashi Y, Shiode N, Saito S, Ikari Y, Kimura T, Hosokawa J, Nakamura M, Kotani J, Kozuma K, Mitsudo K. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J 2013;166:527-33. [PMID: 24016503 DOI: 10.1016/j.ahj.2013.07.002] [Cited by in Crossref: 91] [Cited by in F6Publishing: 70] [Article Influence: 10.1] [Reference Citation Analysis]
52 Brambilla N, Ferrario M, Repetto A, Bramucci E, Angoli L, Canosi U, Rosso R, Ferlini M, Klersy C, Tavazzi L. Use of sirolimus-eluting stents for treatment of in-stent restenosis: long-term follow-up: . Journal of Cardiovascular Medicine 2007;8:699-705. [DOI: 10.2459/jcm.0b013e328010395d] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
53 Abdelmegid MA, Ahmed TA, Kato M, Ando K, Domei T, Iwabuchi M, Nobuyoshi M. Drug-eluting stents or balloon angioplasty for drug-eluting stent-associated restenosis: An observational follow-up study of first-time versus repeated restenosis. J Saudi Heart Assoc 2017;29:76-83. [PMID: 28373780 DOI: 10.1016/j.jsha.2016.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, Otaegui I, Masotti M, Zueco J, Veláquez M, Sanchís J, García-Touchard A, Lázaro-García R, Moreu J, Bethencourt A, Cuesta J, Rivero F, Cárdenas A, Gonzalo N, Jiménez-Quevedo P, Fernández C; RIBS V Study Investigators. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial. JACC Cardiovasc Interv 2016;9:1246-55. [PMID: 27339840 DOI: 10.1016/j.jcin.2016.03.037] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
55 Dixon SR, Grines CL, O’neill WW. The Year in Interventional Cardiology. Journal of the American College of Cardiology 2007;50:270-85. [DOI: 10.1016/j.jacc.2007.04.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
56 Garcia-guimaraes M, Antuña P, Maruri-sanchez R, Vera A, Cuesta J, Bastante T, Rivero F, Alfonso F. Calcified neoatherosclerosis causing in-stent restenosis: prevalence, predictors, and implications. Coronary Artery Disease 2019;30:1-8. [DOI: 10.1097/mca.0000000000000669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
57 Demaria AN, Ben-yehuda O, Feld GK, Ginsburg GS, Greenberg BH, Lew WY, Lima JA, Maisel AS, Narula J, Sahn DJ, Tsimikas S. Highlights of the Year in JACC2006. Journal of the American College of Cardiology 2007;49:509-27. [DOI: 10.1016/j.jacc.2006.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63:2659-2673. [PMID: 24632282 DOI: 10.1016/j.jacc.2014.02.545] [Cited by in Crossref: 291] [Cited by in F6Publishing: 230] [Article Influence: 36.4] [Reference Citation Analysis]
59 Alfonso F. Treatment of drug-eluting stent restenosis the new pilgrimage: quo vadis? J Am Coll Cardiol 2010;55:2717-20. [PMID: 20538164 DOI: 10.1016/j.jacc.2010.03.026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
60 Almalla M, Schröder JW, Pross V, Stegemann E, Marx N, Hoffmann R. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis. Am J Cardiol 2011;108:518-22. [PMID: 21624553 DOI: 10.1016/j.amjcard.2011.03.080] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
61 Möllmann H, Elsässer A, Nef H, Schneider S, Nienaber CA, Richardt G, Weber M, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Pfannebecker T, Senges J, Hamm CW. Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry. Clin Res Cardiol 2008;97:432-40. [DOI: 10.1007/s00392-008-0646-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
62 Rawal S, Sawant AC, Sridhar M, Chaudhry M, Sridhara S, Distler E, Challa S, Parone L, Yazdchi S, Rodriguez J, Daus K, Pershad A. Impact of Intravascular Brachytherapy on Patient-Reported Outcomes in Patients with Coronary Artery Disease. Cardiovasc Revasc Med 2020;21:1550-4. [PMID: 32546383 DOI: 10.1016/j.carrev.2020.05.032] [Reference Citation Analysis]
63 Lee JM, Park J, Kang J, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang HM, Park KW. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv. 2015;8:382-394. [PMID: 25703886 DOI: 10.1016/j.jcin.2014.09.023] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 8.7] [Reference Citation Analysis]
64 Liistro F, Fineschi M, Grotti S, Angioli P, Carrera A, Ducci K, Gori T, Falsini G, Pierli C, Bolognese L. Long-Term Effectiveness and Safety of Sirolimus Stent Implantation for Coronary In-Stent Restenosis. Journal of the American College of Cardiology 2010;55:613-6. [DOI: 10.1016/j.jacc.2009.08.075] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
65 Sun Y, Li L, Su Q, Lu Y. Comparative Efficacy and Safety of Drug-Eluting Stent and Conventional Therapies in Coronary Heart Disease Patients with In-Stent Restenosis: A Meta-Analysis. Cell Biochem Biophys 2014;68:211-29. [DOI: 10.1007/s12013-013-9692-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
66 Theodoropoulos K, Mennuni MG, Dangas GD, Meelu OA, Bansilal S, Baber U, Sartori S, Kovacic JC, Moreno PR, Sharma SK, Mehran R, Kini AS. Resistant in-stent restenosis in the drug eluting stent era: R-ISR in the DES Era. Cathet Cardiovasc Intervent 2016;88:777-85. [DOI: 10.1002/ccd.26559] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
67 Morrison DA. Limitations of stints: a good, albeit imperfect, therapy; for a less than perfect world. Catheter Cardiovasc Interv 2010;75:343-4. [PMID: 20162699 DOI: 10.1002/ccd.22449] [Reference Citation Analysis]
68 Pleva L, Kukla P, Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review. J Geriatr Cardiol. 2018;15:173-184. [PMID: 29662511 DOI: 10.11909/j.issn.1671-5411.2018.02.007] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
69 Colombo A. Repetita iuvant. Catheter Cardiovasc Interv 2008;72:468-9. [PMID: 18819144 DOI: 10.1002/ccd.21787] [Reference Citation Analysis]
70 Alfonso F, Pérez-Vizcayno MJ, García Del Blanco B, García-Touchard A, Masotti M, López-Minguez JR, Iñiguez A, Zueco J, Velazquez M, Cequier A, Lázaro-García R, Martí V, Moris C, Urbano-Carrillo C, Bastante T, Rivero F, Cárdenas A, Gonzalo N, Jiménez-Quevedo P, Fernández C; Restenosis Intra-Stent: Drug-Eluting Balloon vs Everolimus-Eluting Stent (RIBS-IV and V Studies) Investigators (Under the auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology). Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials). Am J Cardiol 2016;117:546-54. [PMID: 26725102 DOI: 10.1016/j.amjcard.2015.11.042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
71 Beijk MA, Claessen BE, Koch KT, Henriques JP, Baan J, Vis MM, Meesterman M, Tijssen JG, Piek JJ, de Winter RJ. One-year clinical outcome after treatment of bare-metal stent in-stent restenosis with the paclitaxel-eluting stent in an unselected cohort. Int J Cardiol 2010;145:608-9. [PMID: 20850881 DOI: 10.1016/j.ijcard.2010.08.062] [Reference Citation Analysis]
72 Tiroch KA, Byrne RA, Kastrati A. Pharmacological prevention and management of restenosis. Expert Opinion on Pharmacotherapy 2010;11:1855-72. [DOI: 10.1517/14656566.2010.485610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
73 Abe M, Kimura T, Morimoto T, Taniguchi T, Yamanaka F, Nakao K, Yagi N, Kokubu N, Kasahara Y, Kataoka Y, Otsuka Y, Kawamura A, Miyazaki S, Nakao K, Horiuchi K, Ito A, Hoshizaki H, Kawaguchi R, Setoguchi M, Inada T, Kishi K, Sakamoto H, Morioka N, Imai M, Shiomi H, Nonogi H, Mitsudo K. Sirolimus-Eluting Stent Versus Balloon Angioplasty for Sirolimus-Eluting Stent Restenosis: Insights From the j-Cypher Registry. Circulation 2010;122:42-51. [DOI: 10.1161/circulationaha.109.905802] [Cited by in Crossref: 35] [Cited by in F6Publishing: 4] [Article Influence: 2.9] [Reference Citation Analysis]
74 Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases 2017; 5(2): 40-45 [PMID: 28255546 DOI: 10.12998/wjcc.v5.i2.40] [Reference Citation Analysis]
75 Völz S, Angerås O, Odenstedt J, Ioanes D, Haraldsson I, Dworeck C, Redfors B, Råmunddal T, Albertsson P, Petursson P, Omerovic E. Sustained risk of stent thrombosis and restenosis in first generation drug-eluting Stents after One Decade of Follow-up: A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Catheter Cardiovasc Interv 2018;92:E403-9. [DOI: 10.1002/ccd.27655] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Alfonso F, Sandoval J, Pérez-Vizcayno MJ, Cárdenas A, Gonzalo N, Jiménez-Quevedo P, Ibáñez B, Núñez-Gil I, Rivero F, Escaned J, Fernández-Ortíz A, Macaya C. Mechanisms of balloon angioplasty and repeat stenting in patients with drug-eluting in-stent restenosis. Int J Cardiol 2015;178:213-20. [PMID: 25464257 DOI: 10.1016/j.ijcard.2014.10.139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
77 Bourantas CV, Garg S, Naka KK, Thury A, Hoye A, Michalis LK. Focus on the research utility of intravascular ultrasound - comparison with other invasive modalities. Cardiovasc Ultrasound 2011;9:2. [PMID: 21276268 DOI: 10.1186/1476-7120-9-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
78 Her AY, Shin ES. Current Management of In-Stent Restenosis. Korean Circ J. 2018;48:337-349. [PMID: 29737639 DOI: 10.4070/kcj.2018.0103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
79 Chevalier B, Moulichon R, Teiger E, Brunel P, Metzger J, Pansieri M, Carrie D, Stoll H, Wittebols K, Spaulding C, Fajadet J; FOR THE CRISTAL INVESTIGATORS. One-Year Results of the CRISTAL Trial, a Randomized Comparison of Cypher Sirolimus-Eluting Coronary Stents versus Balloon Angioplasty for Restenosis of Drug-Eluting Stents: ONE-YEAR RESULTS OF THE CRISTAL TRIAL. Journal of Interventional Cardiology 2012;25:586-95. [DOI: 10.1111/j.1540-8183.2012.00769.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
80 Kufner S, Hausleiter J, Ndrepepa G, Schulz S, Bruskina O, Byrne RA, Fusaro M, Kastrati A, Schömig A, Mehilli J; OSIRIS Trial Investigators. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. JACC Cardiovasc Interv 2009;2:1142-8. [PMID: 19926058 DOI: 10.1016/j.jcin.2009.08.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
81 Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897-1907. [PMID: 21109112 DOI: 10.1016/j.jacc.2010.07.028] [Cited by in Crossref: 469] [Cited by in F6Publishing: 375] [Article Influence: 42.6] [Reference Citation Analysis]
82 Nicolais C, Lakhter V, Virk HUH, Sardar P, Bavishi C, O'Murchu B, Chatterjee S. Therapeutic Options for In-Stent Restenosis. Curr Cardiol Rep 2018;20:7. [PMID: 29435779 DOI: 10.1007/s11886-018-0952-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
83 Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018;. [PMID: 30165437 DOI: 10.1093/eurheartj/ehy394] [Cited by in Crossref: 1826] [Cited by in F6Publishing: 1379] [Article Influence: 913.0] [Reference Citation Analysis]
84 Giustino G, Colombo A, Camaj A, Yasumura K, Mehran R, Stone GW, Kini A, Sharma SK. Coronary In-Stent Restenosis: JACC State-of-the-Art Review. J Am Coll Cardiol 2022;80:348-72. [PMID: 35863852 DOI: 10.1016/j.jacc.2022.05.017] [Reference Citation Analysis]
85 Lee MS, Banka G. In-stent Restenosis. Interventional Cardiology Clinics 2016;5:211-20. [DOI: 10.1016/j.iccl.2015.12.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
86 Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention 2022;18:e103-23. [PMID: 35656726 DOI: 10.4244/EIJ-D-21-01034] [Reference Citation Analysis]
87 Silber S, Borggrefe M, Böhm M, Hoffmeister H, Dietz R, Ertl G, Heusch G. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden Koronarstents (DES): Eine evidenzbasierte Analyse von 71 randomisierten Studien mit 28.984 Patienten. Kardiologe 2007;1:84-111. [DOI: 10.1007/s12181-007-0012-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
88 Elgendy IY, Mahmoud AN, Elgendy AY, Mojadidi MK, Elbadawi A, Eshtehardi P, Pérez-vizcayno MJ, Wayangankar SA, Jneid H, David Anderson R, Alfonso F. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials. Cardiovascular Revascularization Medicine 2019;20:612-8. [DOI: 10.1016/j.carrev.2018.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Abizaid A. Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag 2007;3:191-201. [PMID: 17580729 DOI: 10.2147/vhrm.2007.3.2.191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
90 Vaquerizo B, Serra A, Miranda-guardiola F, Martínez V, Antoni Gómez-hospital J, Iñiguez A, Fernández E, Ramón Rumoroso J, Bosa F, Otaegui I. One-year Outcomes with Angiographic Follow-Up of Paclitaxel-Eluting Balloon for the Treatment of In-Stent Restenosis: Insights from Spanish Multicenter Registry: ONE-YEAR OUTCOMES OF PACLITAXEL ELUTING BALLOON FOR IN-STENT RESTENOSIS. Journal of Interventional Cardiology 2011;24:518-28. [DOI: 10.1111/j.1540-8183.2011.00667.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
91 Mamuti W, Ablimit A, Kelimu W, Rao F, Jiamali A, Zhang W, Pei X, Zhang F. Comparison of drug-eluting balloon versus drug-eluting stent in patients with in-stent restenosis: insight from randomized controlled trials. Int J Cardiol 2015;179:424-9. [PMID: 25465304 DOI: 10.1016/j.ijcard.2014.11.114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
92 Almalla M, Schröder J, Pross V, Marx N, Hoffmann R. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis: Treatment of Drug-Eluting Stent Restenosis. Cathet Cardiovasc Intervent 2014;83:881-7. [DOI: 10.1002/ccd.25072] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
93 Siontis GC, Stefanini GG, Mavridis D, Siontis KC, Alfonso F, Pérez-Vizcayno MJ, Byrne RA, Kastrati A, Meier B, Salanti G, Jüni P, Windecker S. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 2015;386:655-64. [PMID: 26334160 DOI: 10.1016/S0140-6736(15)60657-2] [Cited by in Crossref: 177] [Cited by in F6Publishing: 32] [Article Influence: 25.3] [Reference Citation Analysis]
94 Garg S, Serruys PW. Coronary Stents. Journal of the American College of Cardiology 2010;56:S1-S42. [DOI: 10.1016/j.jacc.2010.06.007] [Cited by in Crossref: 353] [Cited by in F6Publishing: 273] [Article Influence: 29.4] [Reference Citation Analysis]
95 Byrne R, Iijima R, Mehilli J, Pache J, Schulz S, Schömig A, Kastrati A. Tratamiento de la reestenosis de stents liberadores de paclitaxel mediante implantación de stents liberadores de sirolimus. Resultados angiográficos y clínicos. Revista Española de Cardiología 2008;61:1134-9. [DOI: 10.1157/13127844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
96 Gao S, Shen J, Mukku VK, Wang MJ, Akhtar M, Liu W. Efficacy of Drug-Eluting Balloons for Patients With In-Stent Restenosis: A Meta-Analysis of 8 Randomized Controlled Trials. Angiology 2016;67:612-21. [PMID: 26483569 DOI: 10.1177/0003319715611826] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
97 Marquis-Gravel G, Matteau A, Potter BJ, Gobeil F, Noiseux N, Stevens LM, Mansour S. Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population. Arq Bras Cardiol 2017;109:277-83. [PMID: 28977052 DOI: 10.5935/abc.20170142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Alfonso F, Pérez-vizcayno M, Hernandez R, Fernandez C, Escaned J, Bañuelos C, Bethencourt A, López-mínguez JR, Angel J, Cequier A, Sabaté M, Morís C, Zueco J, Seabra-gomes R; For the Restenosis Intra-Stent: Balloon Angioplasty Versus Elective Stent Implantation (RIBS-I) and Restenosis Intra-Stent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Investigators. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: Results of a pooled analysis of two randomized studies. Cathet Cardiovasc Intervent 2008;72:459-67. [DOI: 10.1002/ccd.21694] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
99 Dauerman HL. Treatment of Stent Restenosis. Journal of the American College of Cardiology 2006;47:2161-3. [DOI: 10.1016/j.jacc.2006.03.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
100 Alfonso F, Pérez-Vizcayno MJ, Hernández R, Bethencourt A, Martí V, López-Mínguez JR, Angel J, Iñiguez A, Morís C, Cequier A, Sabaté M, Escaned J, Jiménez-Quevedo P, Bañuelos C, Suárez A, Macaya C; RIBS-II Investigators. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol 2008;52:1621-7. [PMID: 18992651 DOI: 10.1016/j.jacc.2008.08.025] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
101 Zhao L, Zhu W, Zhang X, He D, Guo C. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC Cardiovasc Disord 2017;17:16. [PMID: 28061808 DOI: 10.1186/s12872-016-0445-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]